

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Kunz et al.	Confirmation No.:	1690
Application No.:	09/910,388	Art Unit:	1652
Filed:	July 20, 2001	Examiner:	Robinson, Hope A.
For:	THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS	Attorney Docket No.:	10177-211-999

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicants respectfully direct the Examiner's attention to references **A01-02** and **D01-05** listed on the attached List of References Cited by Applicant.

References **A01-02** are issued United States patents and therefore are not being submitted pursuant to 37 C.F.R. § 1.98(a)(2)(ii). References **D01-02** are Office Actions issued for copending U.S. Application No. 11/703,191 ("the '191 application"), and references **D03-05** are Office Actions issued for copending U.S. Application No. 11/679,650 ("the '650 application"). The above-referenced application, the '191 application, and the '650 application all claim priority to U.S. Application No. 07/767,254 under 35 U.S.C. § 120. Copies of references **D01-05** are not provided, and the Examiner's attention is directed to the prosecution files of the '191 application and the '650 application for copies of these references.


Identification of the listed references is not to be construed as an admission of Attorneys for Applicants or Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is being filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of a final Office Action, a notice of allowance, or an action that otherwise closes prosecution in the application. Pursuant to 37 C.F.R. §§ 1.97(c) and 1.17(p), the fee for this submission is estimated to be \$180.00. Please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: December 22, 2008

  
Gidon D. Stern 27,469  
(Reg. No.)

**JONES DAY**  
222 East 41st Street  
New York, New York 10017  
(212) 326-3939